Literature DB >> 28534511

Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms.

C Unger1, N Kramer1, D Unterleuthner1, M Scherzer1, A Burian1, A Rudisch2, M Stadler1, M Schlederer3, D Lenhardt4, A Riedl1,2, S Walter1, A Wernitznig2, L Kenner3,5,6, M Hengstschläger1, J Schüler4, W Sommergruber2, H Dolznig1.   

Abstract

The insulin-like growth factor (IGF)2/IGF1 receptor (IGF1R) signaling axis has an important role in intestinal carcinogenesis and overexpression of IGF2 is an accepted risk factor for colorectal cancer (CRC) development. Genetic amplifications and loss of imprinting contribute to the upregulation of IGF2, but insufficiently explain the extent of IGF2 expression in a subset of patients. Here, we show that IGF2 was specifically induced in the tumor stroma of CRC and identified cancer-associated fibroblasts (CAFs) as the major source. Further, we provide functional evidence that stromal IGF2, via the paracrine IGF1R/insulin receptor axis, activated pro-survival AKT signaling in CRC cell lines. In addition to its effects on malignant cells, autocrine IGF2/IGF1R signaling in CAFs induced myofibroblast differentiation in terms of alpha-smooth muscle actin expression and contractility in floating collagen gels. This was further augmented in concert with transforming growth factor-β (TGFβ) signaling suggesting a cooperative mechanism. However, we demonstrated that IGF2 neither induced TGFβ/smooth muscle actin/mothers against decapentaplegic (SMAD) signaling nor synergized with TGFβ to hyperactivate this pathway in two dimensional and three dimensional cultures. IGF2-mediated physical matrix remodeling by CAFs, but not changes in extracellular matrix-modifying proteases or other secreted factors acting in a paracrine manner on/in cancer cells, facilitated subsequent tumor cell invasion in organotypic co-cultures. Consistently, colon cancer cells co-inoculated with CAFs expressing endogenous IGF2 in mouse xenograft models exhibited elevated invasiveness and dissemination capacity, as well as increased local tumor regrowth after primary tumor resection compared with conditions with IGF2-deficient CAFs. In line, expression of IGF2 correlated with elevated relapse rates and poor survival in CRC patients. In agreement with our results, high-level coexpression of IGF2 and TGFβ was predicting adverse outcome with higher accuracy than increased expression of the individual genes alone. Taken together, we demonstrate that stroma-induced IGF2 promotes colon cancer progression in a paracrine and autocrine manner and propose IGF2 as potential target for tumor stroma cotargeting strategies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28534511     DOI: 10.1038/onc.2017.116

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  87 in total

1.  The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.

Authors:  J H Park; C H Richards; D C McMillan; P G Horgan; C S D Roxburgh
Journal:  Ann Oncol       Date:  2014-01-23       Impact factor: 32.976

2.  IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

Authors:  Eugenia R Zanella; Francesco Galimi; Francesco Sassi; Giorgia Migliardi; Francesca Cottino; Simonetta M Leto; Barbara Lupo; Jessica Erriquez; Claudio Isella; Paolo M Comoglio; Enzo Medico; Sabine Tejpar; Eva Budinská; Livio Trusolino; Andrea Bertotti
Journal:  Sci Transl Med       Date:  2015-01-28       Impact factor: 17.956

3.  Differential activation of IGF-II promoters P3 and P4 in Caco-2 cells during growth and differentiation.

Authors:  P Singh; B Dai; R L Given; X Lu; P E Holthuizen
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

Review 4.  The actin-MRTF-SRF gene regulatory axis and myofibroblast differentiation.

Authors:  Eric M Small
Journal:  J Cardiovasc Transl Res       Date:  2012-08-17       Impact factor: 4.132

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  The compliance of collagen gels regulates transforming growth factor-beta induction of alpha-smooth muscle actin in fibroblasts.

Authors:  P D Arora; N Narani; C A McCulloch
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

Review 7.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

8.  Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells.

Authors:  Cedric Gaggioli; Steven Hooper; Cristina Hidalgo-Carcedo; Robert Grosse; John F Marshall; Kevin Harrington; Erik Sahai
Journal:  Nat Cell Biol       Date:  2007-11-25       Impact factor: 28.824

9.  Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.

Authors:  A F Olumi; G D Grossfeld; S W Hayward; P R Carroll; T D Tlsty; G R Cunha
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

10.  How to calculate sample size in animal studies?

Authors:  Jaykaran Charan; N D Kantharia
Journal:  J Pharmacol Pharmacother       Date:  2013-10
View more
  23 in total

1.  The regulatory mechanism of LncRNA-mediated ceRNA network in osteosarcoma.

Authors:  Chengsen Lin; Jifeng Miao; Shijie Liao; Yun Liu; Juliang He; Wenyu Feng; Xianxiang Chen; Xiaohong Jiang; Jianhong Liu; Boxiang Li; Qian Huang
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

2.  Critical role of SOX2-IGF2 signaling in aggressiveness of bladder cancer.

Authors:  Yu-Fan Chiu; Chia-Chang Wu; Ming-Han Kuo; Chia-Cheng Miao; Ming-Yi Zheng; Pei-Yu Chen; Sheng-Chieh Lin; Junn-Liang Chang; Yuan-Hung Wang; Yu-Ting Chou
Journal:  Sci Rep       Date:  2020-05-19       Impact factor: 4.379

Review 3.  Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies.

Authors:  Go J Yoshida; Arata Azuma; Yukiko Miura; Akira Orimo
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

Review 4.  IGF signalling in germ cells and testicular germ cell tumours: roles and therapeutic approaches.

Authors:  J Selfe; J M Shipley
Journal:  Andrology       Date:  2019-06-09       Impact factor: 3.842

5.  Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses.

Authors:  Neil Murphy; Robert Carreras-Torres; Mingyang Song; Andrew T Chan; Richard M Martin; Nikos Papadimitriou; Niki Dimou; Konstantinos K Tsilidis; Barbara Banbury; Kathryn E Bradbury; Jelena Besevic; Sabina Rinaldi; Elio Riboli; Amanda J Cross; Ruth C Travis; Claudia Agnoli; Demetrius Albanes; Sonja I Berndt; Stéphane Bézieau; D Timothy Bishop; Hermann Brenner; Daniel D Buchanan; N Charlotte Onland-Moret; Andrea Burnett-Hartman; Peter T Campbell; Graham Casey; Sergi Castellví-Bel; Jenny Chang-Claude; María-Dolores Chirlaque; Albert de la Chapelle; Dallas English; Jane C Figueiredo; Steven J Gallinger; Graham G Giles; Stephen B Gruber; Andrea Gsur; Jochen Hampe; Heather Hampel; Tabitha A Harrison; Michael Hoffmeister; Li Hsu; Wen-Yi Huang; Jeroen R Huyghe; Mark A Jenkins; Temitope O Keku; Tilman Kühn; Sun-Seog Kweon; Loic Le Marchand; Christopher I Li; Li Li; Annika Lindblom; Vicente Martín; Roger L Milne; Victor Moreno; Polly A Newcomb; Kenneth Offit; Shuji Ogino; Jennifer Ose; Vittorio Perduca; Amanda I Phipps; Elizabeth A Platz; John D Potter; Conghui Qu; Gad Rennert; Lori C Sakoda; Clemens Schafmayer; Robert E Schoen; Martha L Slattery; Catherine M Tangen; Cornelia M Ulrich; Franzel J B van Duijnhoven; Bethany Van Guelpen; Kala Visvanathan; Pavel Vodicka; Ludmila Vodickova; Veronika Vymetalkova; Hansong Wang; Emily White; Alicja Wolk; Michael O Woods; Anna H Wu; Wei Zheng; Ulrike Peters; Marc J Gunter
Journal:  Gastroenterology       Date:  2019-12-27       Impact factor: 22.682

6.  IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer.

Authors:  Thomas Crezee; Marika H Tesselaar; Martin Jaeger; Katrin Rabold; Willem E Corver; Hans Morreau; Adriana C H Van Engen-Van Grunsven; Jan W A Smit; Romana T Netea-Maier; Theo S Plantinga
Journal:  Oncol Lett       Date:  2021-06-06       Impact factor: 2.967

7.  Factors Secreted by Cancer-Associated Fibroblasts that Sustain Cancer Stem Properties in Head and Neck Squamous Carcinoma Cells as Potential Therapeutic Targets.

Authors:  Saúl Álvarez-Teijeiro; Cristina García-Inclán; M Ángeles Villaronga; Pedro Casado; Francisco Hermida-Prado; Rocío Granda-Díaz; Juan P Rodrigo; Fernando Calvo; Nagore Del-Río-Ibisate; Alberto Gandarillas; Francisco Morís; Mario Hermsen; Pedro Cutillas; Juana M García-Pedrero
Journal:  Cancers (Basel)       Date:  2018-09-17       Impact factor: 6.639

8.  Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer.

Authors:  Victoria Stary; Brigitte Wolf; Daniela Unterleuthner; Julia List; Merjem Talic; Johannes Laengle; Andrea Beer; Johanna Strobl; Georg Stary; Helmut Dolznig; Michael Bergmann
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

9.  Destruxin B Suppresses Drug-Resistant Colon Tumorigenesis and Stemness Is Associated with the Upregulation of miR-214 and Downregulation of mTOR/β-Catenin Pathway.

Authors:  Szu-Yuan Wu; Yan-Jiun Huang; Yew-Min Tzeng; Chi-Ying F Huang; Michael Hsiao; Alexander T H Wu; Tse-Hung Huang
Journal:  Cancers (Basel)       Date:  2018-09-25       Impact factor: 6.639

10.  Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3.

Authors:  Sameer A Greenall; Jacqueline Donoghue; Terrance G Johns; Timothy E Adams
Journal:  Transl Oncol       Date:  2018-06-22       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.